Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Picard Medical, Inc. (0002030617) (Issuer)
Fastest customizable press release news feed in the world
TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural "Hands-On Training Day" at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston on March 1st 2026. This interactive, case-based program hosted for the first time at the conference will bring together leading clinicians and innovators to advance education in temporary and durable mechanical circulatory support, hemodynamic monitoring, and the management of
Invitation-only program at Houston Methodist, one of the top heart transplant centers in the U.S., highlights the growing need for SynCardia Total Artificial Heart technology. Training initiative at Houston Methodist is expected to enable expanded adoption of the SynCardia Total Artificial Heart through further education. TUCSON, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will host an exclusive, invitation-only "SynCardia Total Artificial Heart Training Village" at Hous
TUCSON, Ariz., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that University of California, San Francisco (UCSF) Health has successfully performed its first heart transplant in a patient who had previously been supported with the SynCardia Total Artificial Heart, marking an important clinical milestone in the treatment of advanced biventricular heart failure. UCSF Health is the U.S. News & World Report 2025-2026 top-ranked hospital in California. UCSF announced in a press release yesterd
TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th International Course on Mechanical Circulatory Support (MCS) and New Technologies in Advanced Heart Failure (HF) congress, being held February 15th - 18th, 2026 in Barcelona, Spain. Details of the pres
TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company's fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. Schuster will review preclinical experience with SynCardia's next-generation, fully implantable total artificial heart platform, Emperor. The presentation will include bench and acute in vivo data
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management. Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System's / Picard Medical's
TUCSON, Ariz., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that on January 5, 2026 SynCardia entered into a development collaboration agreement (the "Agreement") with Hydrix Services Pty Ltd ("Hydrix"), a wholly owned subsidiary of Hydrix Limited (ASX: HYD), to commence an initial development phase for SynCardia's next-generation, fully implantable Total Artificial Heart (TAH) technology, known as the Emperor. As a fully implantable TAH, Emperor would eliminate the use of an external dr
TUCSON, Ariz., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference ("JPM week") including at LifeSci Advisors' Corporate Access Event and Lifeblood and Goodwin's CEO-Only MedTech Forum. Information on both events is below. Lifeblood and Goodwin's MedTech CEO-Only ForumDate: January 12, 2026Format: Invite-only discussion forumLocation: InterCont
TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that it would begin to incorporate an additional design component of an FDA-cleared accessory, CPC1 "Connector Covers", into its SynCardia Total Artificial Heart (STAH) design that is intended to provide comfort during daily activities while reinforcing system safety and reliability. Specifically, the CPC Connector Covers will offer an extra layer of protection over the metal release buttons that
TUCSON, Ariz., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical and SynCardia Systems, LLC, has been elected to the Board of Directors of the Arizona Bioindustry Association (AZBio), the state affiliate in Arizona of the Biotechnology Industry Organization (BIO), the preeminent national association for biotechnology companies His term serving on the board will extend through December 2028.
8-K - Picard Medical, Inc. (0002030617) (Filer)
DEFR14A - Picard Medical, Inc. (0002030617) (Filer)
DEF 14A - Picard Medical, Inc. (0002030617) (Filer)
SCHEDULE 13G - Picard Medical, Inc. (0002030617) (Subject)
PRE 14A - Picard Medical, Inc. (0002030617) (Filer)
424B3 - Picard Medical, Inc. (0002030617) (Filer)
EFFECT - Picard Medical, Inc. (0002030617) (Filer)
S-1/A - Picard Medical, Inc. (0002030617) (Filer)
S-8 - Picard Medical, Inc. (0002030617) (Filer)
8-K - Picard Medical, Inc. (0002030617) (Filer)